Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy targets Platinum-Resistant ovarian cancer

NCT ID NCT04516447

Disease control Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. About 172 participants will receive different drug combinations to find the safest dose and check for side effects. The goal is to control the disease, not cure it, as ongoing treatment is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 172 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2020

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA: For Part 1: * Histologically or cytologically confirmed FIGO Stage III/IV high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal carcinoma. * Subjects must have received 1 or 2 prior therapeutic regimens/lines of therapy in the advanced or metastatic setting. At least one regimen must have contained cisplatin or carboplatin. * The disease must be platinum resistant (ie, the PFI must have been \< 6 months). Platinum refractory disease (ie, PD during first-line platinum-based therapy) is allowed. For Part 2 Dose Escalation: Prior therapy: • Subjects must have received 6 cycles of platinum-based doublet chemotherapy in the 1L or 2L setting as their most recent therapy Response to prior platinum therapy: 1. In the 1L setting: Complete Response, Partial Response, or Stable Disease to platinum-based chemotherapy. 2. In the 2L setting: 1. Progressive Disease \>183 days after receiving the last dose of platinum chemotherapy in the 1L setting, 2. Complete Response, Partial Response, or Stable Disease to 2L platinum-based chemotherapy. * Adequate hematologic, and organ function For Part 2 Dose Expansion: * Subjects must have at least 4 cycles of platinum-based chemotherapy in 2L and have Complete Response, Partial Response, or Stable Disease * Subjects must have progressed while on a PARP inhibitor for 1L maintenance Additional protocol-defined inclusion criteria may apply EXCLUSION CRITERIA: * Histology of abdominal adenocarcinoma of unknown origin or diagnosis of a borderline ovarian tumor. * Subjects with carcinosarcomas (even if there is a serous component) * A serious illness or medical condition(s) * Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy. Additional protocol-defined exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrioid fallopian tube carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial fallopian tube cancer fallopian tube endometrioid adenocarcinoma fallopian tube neoplasm fallopian tube serous adenocarcinoma ovarian carcinoma ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma peritoneum cancer primary peritoneal serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epithelial ovarian cancer Fallopian tube cancer Peritoneal cancer Solid tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    10 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Site 0103

    RECRUITING

    Houston, Texas, 77030, United States

  • Site 0104

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Site 0111

    RECRUITING

    St Louis, Missouri, 53110, United States

  • Site 0173

    RECRUITING

    New York, New York, 10029, United States

  • Site 0191

    RECRUITING

    Providence, Rhode Island, 02905, United States

  • Site 0196

    COMPLETED

    Nashville, Tennessee, 37203, United States

  • Site 0259

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Site 0264

    RECRUITING

    Aurora, Colorado, 80045, United States

  • Site 1001

    COMPLETED

    Banja Luka, 78000, Bosnia and Herzegovina

  • Site 1002

    COMPLETED

    Sarajevo, 71000, Bosnia and Herzegovina

  • Site 1003

    COMPLETED

    Tuzla, 75000, Bosnia and Herzegovina

  • Site 1201

    COMPLETED

    Sofia, 1632, Bulgaria

  • Site 1202

    COMPLETED

    Panagyurishte, 4500, Bulgaria

  • Site 1401

    COMPLETED

    Tbilisi, 0112, Georgia

  • Site 1902

    COMPLETED

    Belgrade, 11080, Serbia

  • Site 2705

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Site 2706

    RECRUITING

    Melbourne, Victoria, 3144, Australia

  • Site 2707

    COMPLETED

    South Brisbane, Queensland, 4101, Australia

  • Site 2708

    COMPLETED

    Sunshine Coast, Queensland, 4556, Australia

  • Site 2709

    COMPLETED

    Adelaide, South Australia, 5000, Australia

  • Site 2716

    RECRUITING

    Melbourne, Victoria, 3121, Australia

  • Site 2901

    COMPLETED

    Busan, South Korea

  • Site 2903

    COMPLETED

    Seoul, 03080, South Korea

  • Site 2904

    COMPLETED

    Seoul, 05505, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.